Beam Therapeutics (BEAM) news
Recent news
Beam Global expects 2Q net loss of ~$3.1M vs ~$4.3M yr ago
Beam Therapeutics (BEAM) reported second-quarter 2026 net loss , or $1.18 per share, according to its latest financial results. This represents a significant increase in losses compared to the prior year period, when the company recorded a $1.00 loss . Revenue for the quarter totaled $490,000,…
AInvest Wire · Aug 14, 2026Prime Medicine owes no monetary damages to Beam Therapeutics
AInvest Wire · Jul 8, 2026Prime Medicine announces positive resolution to arbitration with Beam Therapeutics
AInvest Wire · Jul 8, 2026Beam Therapeutics’s CEO Evans Sells $562.684 of Shares
AInvest Wire · Apr 4, 2025Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate
Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate Beam Therapeutics (BEAM), a leading genetic medicine company, reported its second-quarter financial results on July 24, 2024, beating both GAAP earnings per share (EPS) and sales estimates [1].…
AInvest Wire · Aug 6, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.